We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Detecto

Eurofins Technologies

  Gold Eurofins Technologies, part of the Eurofins Scientific group, is a fast-growing, global provider of diagnostic test k... read more Featured Products: More products

Download Mobile App





Ground-Breaking and Novel Assays to Help Assess Organ and Tissue Damage in Transplant and COVID-19 Patients

By HospiMedica International staff writers
Posted on 22 Mar 2022
Print article
Image: Ground-breaking technologies will assess organ and tissue damage in transplant and COVID-19 patients (Photo courtesy of Pexels)
Image: Ground-breaking technologies will assess organ and tissue damage in transplant and COVID-19 patients (Photo courtesy of Pexels)

A new collaboration will expand access to blood and urine-based cell-free DNA detection methods that will provide healthcare practitioners with highly accurate, non-invasive tools to identify and monitor for infection, rejection, and severity of organ damage in transplant and COVID-19 patients.

Eurofins Viracor, LLC (Lees Summit, MO, USA) has entered into an exclusive license agreement with Cornell University (Ithaca, NY, USA) to commercialize several ground-breaking and novel assays aimed at transforming the clinical management of COVID-19 and transplant patients impacted from tissue damage and infections. Surgical biopsy is critical in tracking damage of COVID-19 in the body, but the procedure can be painful and costly to the patient. Researchers at Cornell have developed an alternative to biopsy – a novel, noninvasive blood test to measure organ injury from COVID-19. The test uses circulating cell-free DNA (cfDNA) to gauge the damage that COVID-19 inflicts on cells, tissues and organs.

Additionally, cfDNA is a highly versatile analyte for monitoring the most critical complications of hematopoietic cell transplantation (HCT) for many blood disorders and cancers, including Graft-Versus-Host Disease, infection, graft failure and disease relapse. The agreement between Eurofins and Cornell will expand access to an innovative blood-based cfDNA methylation sequencing assay for early detection or prediction of major complications related to allogeneic HCT, thus improving the care of stem cell transplant patients. In another application, Eurofins intends to commercialize the novel cfDNA test used to identify the presence of urinary tract infections in kidney transplant patients and quantify the degree of damage to the kidney and bladder.

Related Links:
Eurofins Viracor, LLC
Cornell University 

BMP Whole Blood Analyzer: GEM Premier ChemSTAT
New
Gold Supplier
STI Real-Time PCR Test
Neisseria Gonorrhoeae/Chlamydia Trachomatis/U.urealyticum Real-Time PCR Kit
New
Cancer Biomarker Test
Xpert Bladder Cancer Detection
New
Antimicrobial Susceptibility Testing Software
MICRONAUT6 Software

Print article
Radcal

Channels

AI

view channel
Image: AI transforms smartwatch ECG signals into a diagnostic tool for heart failure (Photo courtesy of Pexels)

AI-Based Smartwatch Accurately Detects Heart Failure Using ECG Signals

People with a weak heart pump might not have symptoms, but this common form of heart disease affects about 2% of the population and 9% of people over 60. When the heart cannot pump enough oxygen-rich blood,... Read more

Critical Care

view channel
Image: PATHFAST is a compact immunoanalyzer with superior assay performance (Photo courtesy of PHC Europe)

Benchtop Immunoanalyzer Delivers Lab Quality Results for Cardiology, Intensive Care and Emergency Wards at POC

A compact immunoanalyzer with superior assay performance combines the accuracy of a full-scale lab analyzer with the flexibility of a mobile solution, making it an ideal analysis system for laboratories,... Read more

Surgical Techniques

view channel
Image: Bioelectric medicine could stem excessive blood loss (Photo courtesy of Pexels)

Wearable Neurostimulation Solution Could Stem Excessive Blood Loss in the OR

A wearable neurostimulation solution focused on lessening excessive blood loss could save precious time for surgical teams in the operating room. A collaboration between Spark Biomedical, Inc.... Read more

Patient Care

view channel
Image: The digital stretcher scales are designed specifically for emergent situations in hospitals and emergency rooms (Photo courtesy of DETECTO)

Portable High-Capacity Digital Stretcher Scales Provide Precision Weighing for Patients in ER

For emergency arrivals into a hospital, time is of the essence for gathering patient weights. Now, digital stretcher scales specifically designed for emergent situations in hospitals and emergency rooms... Read more

Health IT

view channel
Image: Using digital data can improve health outcomes (Photo courtesy of Unsplash)

Electronic Health Records May Be Key to Improving Patient Care, Study Finds

When a patient gets transferred from a hospital to a nearby specialist or rehabilitation facility, it is often difficult for personnel at the new facility to access the patient’s electronic health records... Read more

Business

view channel
Image: The global visualization instruments for MIS market is estimated to surpass USD 21 billion by 2031 (Photo courtesy of Pexels)

Global Visualization Instruments for MIS Market Driven by Increasing Demand for Endoscopy Procedures

The last few years have witnessed an increase in patient preference for medical surgeries that involve fewer incisions. As a result, the demand for visualization instruments, which aid in achieving improved... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.